[Efficacy analysis of selinexor combined with hypomethylating agent in the treatment of refractory/relapsed acute myeloid leukemia exposed to venetoclax].
作者信息
Zhang J, Song B Q, Kong X, Liu Y, Yang H L, Zong L H, Kong J Y, Xu Y, Qiu H Y, Wu D P
机构信息
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2023 Nov 14;44(11):936-939. doi: 10.3760/cma.j.issn.0253-2727.2023.11.009.
Abstract
摘要
相似文献
1
[Efficacy analysis of selinexor combined with hypomethylating agent in the treatment of refractory/relapsed acute myeloid leukemia exposed to venetoclax].
Zhonghua Xue Ye Xue Za Zhi. 2023 Nov 14;44(11):936-939. doi: 10.3760/cma.j.issn.0253-2727.2023.11.009.
2
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
Haematologica. 2021 Mar 1;106(3):894-898. doi: 10.3324/haematol.2020.252569.
3
Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
Br J Haematol. 2022 Aug;198(3):e35-e37. doi: 10.1111/bjh.18229. Epub 2022 May 4.
4
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
Haematologica. 2020 Nov 1;105(11):2659-2663. doi: 10.3324/haematol.2019.242826.
5
Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
J BUON. 2021 Sep-Oct;26(5):2026-2032.
6
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.
7
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10.
8
Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
Chemotherapy. 2022;67(3):178-182. doi: 10.1159/000519882. Epub 2022 Mar 18.
9
The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
Hematology. 2024 Dec;29(1):2350319. doi: 10.1080/16078454.2024.2350319. Epub 2024 May 15.
10
Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
Am J Hematol. 2024 Apr;99(4):515-518. doi: 10.1002/ajh.27256. Epub 2024 Feb 20.
引用本文的文献
1
[Efficacy of selinexor combined with subcutaneous decitabine in myeloid malignancies refractory to or relapsed after venetoclax therapy].
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):473-477. doi: 10.3760/cma.j.cn121090-20240920-00358.
2
[The clinical safety and efficacy of selinexor combined with venetoclax and azactitidine induction therapy in relapsed and refractory acute myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):772-775. doi: 10.3760/cma.j.cn121090-20231031-00241.
本文引用的文献
1
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
2
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
Invest New Drugs. 2022 Aug;40(4):738-746. doi: 10.1007/s10637-022-01251-5. Epub 2022 May 16.
3
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
Haematologica. 2021 Mar 1;106(3):894-898. doi: 10.3324/haematol.2020.252569.
4
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.
Blood Adv. 2020 Feb 11;4(3):586-598. doi: 10.1182/bloodadvances.2019000359.
5
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.
6
Selinexor: First Global Approval.
Drugs. 2019 Sep;79(13):1485-1494. doi: 10.1007/s40265-019-01188-9.
7
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.
8
Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.
Curr Treat Options Oncol. 2019 Feb 11;20(2):15. doi: 10.1007/s11864-019-0612-y.
9
Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
J Cell Mol Med. 2018 Dec;22(12):6099-6111. doi: 10.1111/jcmm.13886. Epub 2018 Sep 14.
10
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
Zotero 插件